Discovering The Potential Therapeutic Applications of ALG13 (G79868)

Target Name: ALG13

NCBI ID: G79868

ALG13

Other Name(s): ALG13 variant 7 | ALG13 UDP-N-acetylglucosaminyltransferase subunit, transcript variant 7 | Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 (isoform 1) | ALG13 variant 2 | Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 | Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 (isoform 6) | EIEE36 | ALG13 variant 1 | ALG13 UDP-N-acetylglucosaminyltransferase subunit | glycosyltransferase 28 domain-containing protein 1 | MDS031 | Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 (isoform 2) | ALG13 UDP-N-acetylglucosaminyltransferase subunit, transcript variant 1 | Glycosyltransferase 28 domain-containing protein 1 | Hematopoietic stem/progenitor cells protein MDS031 | Asparagine-linked glycosylation 13 homolog | YGL047W | ALG13_HUMAN | Tudor domain containing 13 | CDG1S | ALG13 UDP-N-acetylglucosaminyltransferase subunit, transcript variant 2 | TDRD13 | tudor domain containing 13 | ALG13 variant 3 | GLT28D1 | Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 (isoform 3) | Tematopoietic stem/progenitor cells protein MDS031 | DEE36 | hematopoietic stem/progenitor cells protein MDS031 | asparagine-linked glycosylation 13 homolog | CXorf45 | ALG13 UDP-N-acetylglucosaminyltransferase subunit, transcript variant 3 | N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase | UDP-N-acetylglucosamine transferase subunit ALG13 homolog

Discovering The Potential Therapeutic Applications of ALG13

ALG13 (ALG13 variant 7) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell antigen 13 (TCA13) family, which consists of a variety of cytoskeletal proteins that play important roles in the development and maintenance of tissues.

One of the unique features of ALG13 is its ability to interact with the protein PD-L1. PD-L1 is a protein that is expressed in many tissues, including the immune system, and plays a role in suppressing the immune response. By interacting with PD-L1, ALG13 may help to regulate the immune response and promote immune tolerance.

In addition to its potential role in immune regulation, ALG13 is also a potential drug target. Its interaction with PD-L1 makes it a potential target for small molecules that can inhibit PD-L1 function. This could lead to a range of potential therapeutic applications, including the treatment of autoimmune diseases and cancer.

Another potential mechanism by which ALG13 may be involved in disease is its role in the development of fibrosis. Fibrosis is a process in which cells become abnormally persistent and contribute to the development of a variety of diseases, including heart disease and cancer. ALG13 has been shown to be involved in the development of fibrosis in various tissues, and may be a potential therapeutic target for these diseases.

In addition to its potential role in fibrosis, ALG13 is also a potential biomarker for disease. Its expression has been shown to be altered in a variety of diseases, including cancer, heart disease, and neurodegenerative diseases. This may make it a useful tool for the diagnosis and monitoring of these diseases.

Overall, ALG13 is a protein that has significant potential as a drug target and biomarker. Its ability to interact with PD-L1 and its potential role in immune regulation, fibrosis, and disease make it a promising target for small molecules and other therapeutic approaches. Further research is needed to fully understand its function and potential therapeutic applications.

Protein Name: ALG13 UDP-N-acetylglucosaminyltransferase Subunit

Functions: Possible multifunctional enzyme with both glycosyltransferase and deubiquitinase activities

The "ALG13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALG13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets